Biomodulation of cancer chemotherapy for metastatic colorectal cancer: A randomized study of weekly low-dose irinotecan alone Versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations

Anticancer Research

Volumn 23, Issue 2 C, 2003, Pages 1951-1954

  Cerea, G ^a   Vaghi, M ^a   Ardizzoia, A ^a   Villa, S ^b   Bucovec, R ^a   Mengo, S ^a   Gardani, G ^a   Tancini, G ^a   Lissoni, P ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b A MANZONI HOSPITAL   (Italy)

Author keywords

Anti oxidants; Colorectal cancer; Imunomodulating agents; Irinotecan; Melatonin

Indexed keywords

ANTHRACYCLINE; ANTIOXIDANT; CISPLATIN; CYTOTOXIC AGENT; FLUOROURACIL; IMMUNOMODULATING AGENT; IRINOTECAN; MELATONIN; PINEAL BODY HORMONE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOBIOLOGY; IMMUNOMODULATION; MALE; METASTASIS; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MELATONIN; MIDDLE AGED;

EID: 0037524440     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rubinow DR: Brain, behavior and immunity: an interactive system. J Natl Cancer Inst Monogr 10: 79-82, 1990.
2. Jankovic BD: Neuroimmunodulation. From phenomenology to molecular evidence. Ann NY Acad Sci 741: 3-38, 1994.
3. Lissoni P, Cangemi P, Pirato D et al: A review on cancer-psychospiritual status interactions. Neuroendocrinol Lett 22: 175-180, 2001.
4. Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA: Lymphokine-activated killer cell phenomenon. J Exp Med 155: 1823-1841, 1982.
5. Atzpodien J and Kirchner H: Cancer, cytokines and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 68: 1-11, 1990.
6. Maestroni GJM: The immunoneuroendocrine role of melatonin. J Pineal Res 14: 1-10, 1993.
7. Brzezinski A: Melatonin in humans. N Engl J Med 336: 186-195, 1997.
8. Lissoni P: The pineal gland as a central regulator of cytokine network. Neuroendocrinol Lett 20: 343-349, 1999.
9. Lissoni P: Is there a role for melatonin in supportive care? Supp Care Cancer 10: 110-116, 2002.
10. Vijayalaxmi B, Thomas CR, Russel RJ and Herman TS: Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20: 2575-2601, 2002.
11. Chinery R, Brockman JA, Peeler MO et al: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer. Nature Med 3: 1233-1237, 1997.
12. Klauber N, Parangi S, Flynn E, Hamel E and D' Amato RJ: Inhibition of angiogenesis and breast cancer in mice by microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86, 1997.
13. Lissoni P, Tancini G, Paolorossi F et al: Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J Pineal Res 26: 169-173, 1999.
14. Saltz L, Cox JV, Blanke C et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
15. Bartsch H and Bartsch C: Effect of melatonin on experimental tumors under different photoperiods and times of administration. J Neural Transm 52: 269-279, 1981.